Skip to main content
padlock icon - secure page this page is secure

RNA Interference-Based Immunomodulation for Glioblastoma Immune Microenvironment: A Review

Buy Article:

$106.34 + tax (Refund Policy)

Glioblastoma is the most common and devastating primary brain tumor in adults. The clinical treatments of glioblastoma are generally focus on surgical excision, chemotherapy and radiotherapy, while the prognosis remains grim. With the adequate understanding of the unique immunological microenvironment in the central nervous system (CNS) and CNS tumors, immune microenvironment modulation becomes a promising treatment modality in glioma. Studies using RNA interference (RNAi) technology to modulate the immune microenvironment are under an active investigation. Using those therapeutic strategies directly or indirectly react with tumor cells, antigen processing cells (APCs, including microglia and dendritic cells (DCs)) and immune cells (such as T cells and natural killer cells (NK cells)) has been extensively studied. Here, we review the current advances in immune microenvironment modulation for glioblastoma with RNAi approach. We also investigate how the factors, associated with immunosuppression, to combat with glioblastoma, and discuss the deficiency for this anti-glioblastoma strategy. From these, we expect to provide a guidance for the future development of RNAi-based immunomodulation strategy for glioblastoma and establish optimized antitumor therapy for clinical treatments.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Review Article

Publication date: August 1, 2017

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more